“Identification of an antibody against a novel peptide from Porphyromonas gingivalis as a biomarker for rheumatoid arthritis”
Clinical Immunology · 2025
DOI: 10.1016/j.clim.2025.110576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2025. Verfasst von Yung-Ju Yeh und 17 weiteren Autor:innen. Beteiligte Einrichtung: Autoimmune Disease Laboratory, China Medical University Hospital, Taichung, Taiwan; Research and Development Center for Immunology, China Medical Uni…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Porphyromonas gingivalis, Peptides, Antibodies, Bacterial. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, China Medical University Hospital, China Medical University.
Abstract (Originalsprache)
Current serological markers for rheumatoid arthritis (RA) lack sensitivity in early or seronegative disease. We evaluated anti-BR1 antibodies, targeting a Porphyromonas gingivalis RgpA-derived peptide, as a novel biomarker. From 15 peptides screened in a training cohort, BR1 showed the highest diagnostic potential (AUC = 0.9553). In an independent validation cohort, anti-BR1 demonstrated an AUC of 0.7668, with 58.6 % sensitivity and 97.0 % specificity based on a ROC-derived cutoff. Anti-BR1 antibodies were detected in 82 of 140 (58.6 %) RA cases, including 35 of 58 (60.3 %) seronegative patients, and in 16 of 38 (42.1 %) early arthritis (EA) cases, outperforming RF and ACPA. Combining anti-BR1 with RF and ACPA increased the diagnostic yield from 58.6 % to 83.6 % in RA, and from 26.3 % to 55.3 % in EA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Autoimmune Disease Laboratory, China Medical University Hospital, Taichung, Taiwan; Research and Development Center for Immunology, China Medical University, Taichung, Taiwan.
- Research and Development Center for Immunology, China Medical University, Taichung, Taiwan.
- Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
- Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; College of Medicine, China Medical University, Taichung, Taiwan.
- Institute of Biochemistry, Microbiology, Immunology, Chung Shan Medical University, Taichung, Taiwan.
- College of oral medicine, Chung Shan Medical University, Taiwan.
Förderung
- Ministry of Science and Technology of the People's Republic of China
- China Medical University Hospital
- China Medical University
- Ministry of Science and Technology, Taiwan
- National Science and Technology Council
Zitieren
APA
Yeh, Y. J., Peng, H. Y., Xue, T. Y., Li, W. J., Huang, P. H., Yeo, K. J., Huang, C. C., Chen, J. H., Huang, C. M., Chen, D. Y., Lan, J. L., Jan, M. S., Chang, Y. C., Chang, H., Tsai, C. H., Chen, H. C., Liu, S. Y., & Tsay, G. J. (2025). “Identification of an antibody against a novel peptide from Porphyromonas gingivalis as a biomarker for rheumatoid arthritis”. Clinical Immunology. https://doi.org/10.1016/j.clim.2025.110576
Vancouver
Yeh YJ, Peng HY, Xue TY, Li WJ, Huang PH, Yeo KJ, et al. “Identification of an antibody against a novel peptide from Porphyromonas gingivalis as a biomarker for rheumatoid arthritis”. Clinical Immunology. 2025. doi:10.1016/j.clim.2025.110576
BibTeX
@article{Yeh2025,
author = {Yeh, Yung-Ju and Peng, Hsin-Yi and Xue, Ting-Yin and Li, Wei-Jing and Huang, Po-Hao and Yeo, Kai-Jieh and Huang, Chien-Chung and Chen, Jiunn-Horng and Huang, Chung-Ming and Chen, Der-Yuan and Lan, Joung-Liang and Jan, Ming-Shiou and Chang, Yu-Chao and Chang, Han and Tsai, Chun-Hao and Chen, Hui-Chen and Liu, Shin-Yi and Tsay, Gregory J},
title = {“Identification of an antibody against a novel peptide from Porphyromonas gingivalis as a biomarker for rheumatoid arthritis”},
journal = {Clinical Immunology},
year = {2025},
doi = {10.1016/j.clim.2025.110576}
}
EUVIMED